National Centre for Neuroimmunology and Emerging Diseases
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
(Redirected from Griffith University)
The National Centre for Neuroimmunology and Emerging Disease (NCNED) is an Australian research group led by Professors Sonya Marshall-Gradisnik and Donald Staines.[1]
The NCNED is a part of Menzies Health Institute Queensland at Griffith University in south-east Queensland, Australia.[2]
Members[edit | edit source]
In addition to co-directors Professors Marshall-Gradisnik and Staines, full members of the NCNED are:[1]
- Dr Leighton Barnden
- Dr Hélène Cabanas
- Dr Alfred Lam
- Dr Donald Stewart
Potential biomarker[edit | edit source]
In February 2016 the research team led by Profs. Staines and Marshall-Gradisnik announced it had created a diagnostic test for the disease using CD8 T cells.[3][4][5][6][7][8][9] The researchers have submitted patent claims in relation to their discovery.[10][11][12]
Professor Marshall-Gradisnik clarified: "In response to a number of inquiries of this nature we are pleased to advise that we have both published papers, papers in press, and additional data not for publication, which constitutes commercial-in-confidence".[13][14]
Notable studies[edit | edit source]
- May 2019, Validation of impaired Transient Receptor Potential Melastatin 3 ion channel activity in natural killer cells from Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis patients[15] (Full text)
- Aug 2018, Loss of Transient Receptor Potential Melastatin 3 ion channel function in natural killer cells from Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients[16] (Full text)
- May 2016, Novel identification and characterisation of Transient receptor potential melastatin 3 ion channels on Natural Killer cells and B lymphocytes: effects on cell signalling in Chronic fatigue syndrome/Myalgic encephalomyelitis patients[17] (Full text)
- Apr 2016, ERK1/2, MEK1/2 and p38 downstream signalling molecules impaired in CD56dimCD16+ and CD56brightCD16dim/− natural killer cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients[18] (Full text)
- Jan 2016, Genotype Frequencies of Transient Receptor Potential Melastatin M3 Ion Channels and Acetylcholine Muscarinic M3 Receptor Gene Polymorphisms in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis Patients Genotype Frequencies of Transient Receptor Potential Melastatin M3 Ion Channels and Acetylcholine Muscarinic M3 Receptor Gene Polymorphisms in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis Patients[19] (Full text)
- Dec 2015, A Preliminary Comparative Assessment of the Role of CD8+ T Cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis and Multiple Sclerosis[20] (Full text)
- Dec 2015, Pilot Study of Natural Killer Cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis and Multiple Sclerosis[21] (Abstract)
- Sep 2015, Serum Immune Proteins in Moderate and Severe Chronic Fatigue Syndrome/Myalgic Encephalomyelitis Patients, Int J Med Sci, 2015; 12(10): 764–772.
- Aug 2015, Longitudinal analysis of immune abnormalities in varying severities of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients, Journal of Translatqional Medicine, 201513:299
- Conclusions: Severe CFS/ME patients differed from controls and moderate CFS/ME patients over time and expressed significant alterations in iNKT cell phenotypes, CD8+T cell markers, NK cell receptors and γδT cells at 6 months.
- May 2015 - Characterisation of cell functions and receptors in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME), BMC Immunology, 2015 16:35
- May 2015 - Examination of Single Nucleotide Polymorphisms in Acetylcholine Receptors in Chronic Fatigue Syndrome Patients, Immunology and Immunogenetics Insights, 2015:7 7-20. (small study - 115 people with ME/CFS)
- May 2015 - Examination of Single Nucleotide Polymorphisms (SNPs) in Transient Receptor Potential (TRP) Ion Channels in Chronic Fatigue Syndrome Patients[22] (small study - 115 people with ME/CFS)
- Apr 2014 - A comparison of health status in patients meeting alternative definitions for chronic fatigue syndrome/myalgic encephalomyelitis, Health and Quality of Life Outcomes, 2014 12:64
- Results: Patients fulfilling the ICC definition reported significantly lower scores (p < 0.05) for physical functioning, physical role, bodily pain, and social functioning than those that only fulfilled the 1994 CDC definition. ICC patients reported significantly greater (p < 0.05) disability across all domains of the WHO DAS 2.0.
Funding[edit | edit source]
The NCNED is supported by the Queensland Government and philanthropic donors.[23] In 2016, Professors Marshall-Gradisnik and Staines and Dr Samantha Johnston were awarded $4 million (AUS) from the Stafford Fox Medical Research Foundation to accelerate the diagnosis of CFS and the discovery of appropriate treatments.[2] The grant follows on a previous round of funding ($2.5 million) from the same foundation.[2]
Online presence[edit | edit source]
- Twitter - Griffith Health
- Website - Griffith Health
- Website - NCNED
- YouTube - CFS Myths 1, 2, and 3 via Stuart North's playlist of Griffith University's videos.
- Institution
Learn more[edit | edit source]
- Feb 29, 2016, Australian scientists make breakthrough in Chronic Fatigue Syndrome testing, ABC News (Australia)
- Mar 1, 2016, Screening test for Chronic Fatigue Syndrome on its way, Griffith University
See also[edit | edit source]
- Professor Sonya Marshall-Gradisnik
- Professor Donald Staines
- Dr. Peter Smith
- Dr. Richard Kwiatek
- Dr. Hélène Cabanas
- TRPM3
- Diagnostic biomarker
References[edit | edit source]
- ↑ 1.0 1.1 "National Centre for Neuroimmunology and Emerging Diseases". griffith.edu.au. Retrieved October 21, 2019.
- ↑ 2.0 2.1 2.2 Durack, Louise (December 1, 2016). "$4m grant to aid Chronic Fatigue Syndrome diagnosis". Griffith News. Retrieved April 13, 2019.
- ↑ Australian scientists make breakthrough in Chronic Fatigue Syndrome testing, ABC News (Australia), 29 February 2016
- ↑ Griffith Uni claims breakthrough on diagnostic test, #MEAction, February 29, 2016
- ↑ Screening test for Chronic Fatigue Syndrome on its way, Griffith University, 1 March 2016
- ↑ A Preliminary Comparative Assessment of the Role of CD8+ T Cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis and Multiple Sclerosis’., Journal of Immunology Research, Volume 2016 (2016), Article ID 9064529, 8 pages
- ↑ New Screening Test for ME/CFS Announced by Griffith University, CFS Treatment Guide, 5 Mar 2016
- ↑ Chronic fatigue syndrome: new diagnostic tool to speed up treatment and reduce stigma
- ↑ A screening test for chronic fatigue syndrome is ready for the public
- ↑ Patent AusPat 2015904991, IP Australia, 2 December 2015
- ↑ Patent AusPat 2015901567, IP Australia, 1 June 2015
- ↑ Biological markers - WO 2016023077 A1
- ↑ Statement from NCNED, Griffith University, 1 March 2016
- ↑ Letter from Sonya Marshall-Gradisnik, Twitter, 1 March 2016
- ↑ Cabanas, H.; Muraki, K.; Balinas, C.; Eaton-Fitch, N.; Staines, D.; Marshall-Gradisnik, S. (April 23, 2019). "Validation of impaired Transient Receptor Potential Melastatin 3 ion channel activity in natural killer cells from Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis patients". Molecular Medicine. 25. doi:10.1186/s10020-019-0083-4. ISSN 1076-1551. PMC 6480905. PMID 31014226.
- ↑ Cabanas, Hélène; Muraki, Katsuhiko; Eaton, Natalie; Balinas, Cassandra; Staines, Donald; Marshall-Gradisnik, Sonya (August 14, 2018). "Loss of Transient Receptor Potential Melastatin 3 ion channel function in natural killer cells from Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients". Molecular Medicine. 24. doi:10.1186/s10020-018-0046-1. ISSN 1076-1551. PMC 6092868. PMID 30134818.
- ↑ Nguyen, T.; Staines, D.; Nilius, B.; Smith, P.; Marshall-Gradisnik, S. (May 31, 2016). "Novel identification and characterisation of Transient receptor potential melastatin 3 ion channels on Natural Killer cells and B lymphocytes: effects on cell signalling in Chronic fatigue syndrome/Myalgic encephalomyelitis patients". Biological Research. 49 (1): 27. doi:10.1186/s40659-016-0087-2. ISSN 0717-6287. PMC 4888729. PMID 27245705.
- ↑ Huth, Teilah Kathryn; Staines, Donald; Marshall-Gradisnik, Sonya (April 21, 2016). "ERK1/2, MEK1/2 and p38 downstream signalling molecules impaired in CD56dimCD16+ and CD56brightCD16dim/− natural killer cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients". Journal of Translational Medicine. 14 (1): 97. doi:10.1186/s12967-016-0859-z. ISSN 1479-5876. PMC 4839077. PMID 27098723.
- ↑ Marshall-Gradisnik, S.M.; Chacko, A.; Johnston, S.; Smith, P.; Nilius, B.; Staines, D.R. (January 1, 2016). "Genotype Frequencies of Transient Receptor Potential Melastatin M3 Ion Channels and Acetylcholine Muscarinic M3 Receptor Gene Polymorphisms in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis Patients". Immunology and Immunogenetics Insights. 8: III.S37042. doi:10.4137/III.S37042. ISSN 1178-6345.
- ↑ Marshall-Gradisnik, Sonya; Staines, Don; Ramos, Sandra; Johnston, Samantha; Nguyen, Thao; Broadley, Simon; Brenu, Ekua W. (2016). "A Preliminary Comparative Assessment of the Role of CD8". Journal of Immunology Research. Retrieved May 10, 2019.
- ↑ Huth, T.K.; Brenu, E.W.; Ramos, S.; Nguyen, T.; Broadley, S.; Staines, D.; Marshall‐Gradisnik, S. (2016). "Pilot Study of Natural Killer Cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis and Multiple Sclerosis". Scandinavian Journal of Immunology. 83 (1): 44–51. doi:10.1111/sji.12388. ISSN 1365-3083.
- ↑ Marshall-Gradisnik, Sonya M.; Smith, Peter; Brenu, Ekua W.; Nilius, Bernd; Ramos, Sandra B.; Staines, Donald R. (January 1, 2015). "Examination of Single Nucleotide Polymorphisms (SNPs) in Transient Receptor Potential (TRP) Ion Channels in Chronic Fatigue Syndrome Patients". Immunology and Immunogenetics Insights. 7: III.S25147. doi:10.4137/III.S25147. ISSN 1178-6345.
- ↑ NCNED Partnerships
